Lutropin alfa vs Cetrorelix

Head-to-head comparison of Lutropin alfa (Recombinant Human Luteinizing Hormone Alfa) and Cetrorelix (Cetrorelix acetate) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyLutropin alfaCetrorelix
CategorySexual HealthSexual Health
Full NameRecombinant Human Luteinizing Hormone AlfaCetrorelix acetate
Molecular Weight30,000 Da1431.06 Da
Half-Life~10-12 hours~30 hours
Amino AcidsN/A10
Typical Dose75-150 IU per dose0.25 mg SC daily
RouteSubcutaneous/IntramuscularSubcutaneous
Purity≥98%≥98%
Studies Count420300
Research StatusClinicalClinical

Lutropin alfa Benefits

  • stimulates Leydig cells
  • raises endogenous testosterone
  • supports testicular steroidogenesis
  • pairs with FSH for fertility

Cetrorelix Benefits

  • prevents premature ovulation
  • supports IVF cycle control
  • blocks LH surge
  • short-acting pituitary suppression

Lutropin alfa Dosing

75-150 IU SC/IM 2-3x weekly|adjust to testosterone response|combine with FSH when spermatogenesis support is needed

Cetrorelix Dosing

0.25 mg SC daily|start on stimulation day 5-6|protocol-dependent antagonist cycle

Lutropin alfa Side Effects

  • injection-site reactions
  • headache
  • hormonal swings

Cetrorelix Side Effects

  • injection-site reactions
  • headache
  • nausea

Research Overview

Lutropin alfa

Lutropin alfa has been evaluated in fertility protocols to restore LH signaling and endogenous testosterone production. It is a direct research/clinical analogue for men with low gonadotropin drive.

Cetrorelix

Cetrorelix is a cornerstone GnRH antagonist in assisted reproduction, with a fast onset and reversible suppression of LH. Trials show it improves cycle management by reducing premature ovulation during stimulation.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Lutropin alfa stacks with:

Follitropin alfahCG

Cetrorelix stacks with:

FSHhCG
LHtestosteronefertilityclinicalGnRH-antagonistivf